The British Journal of Psychiatry (2008) 193: 501-502. doi: 10.1192/bjp.bp.107.045021
© 2008 The Royal College of Psychiatrists
OPEN ACCESS ARTICLE
Adults with untreated phenylketonuria: out of sight, out of mind
Glynis H. Murphy, BA, MSc, PhD
Tizard Centre, University of Kent, Canterbury
Sally M. Johnson, BSc, MSc
Services for Children and Young People with Learning Disabilities,
Folkestone
Allayne Amos, BSc, PhD
Tizard Centre, University of Kent, Canterbury
Eleanor Weetch, BSc, SRD
National Society for Phenylketonuria, South Yorkshire
Rosemary Hoskin, SRD
Dietetic Services to Learning Disabilities Team, North West
Hertfordshire
Brian Fitzgerald, MB, BcH BAO (NUI), MRCPsych
Chase Farm Hospital, Enfield, Middlesex
Maggie Lilburn, SRD,
Lesley Robertson, BSc, SRD and
Philip Lee, DM, FRCP, FRCPsych
Charles Dent Metabolic Unit, National Hospital for Neurology and
Neurosurgery, London, UK
Correspondence:
Glynis H. Murphy, Tizard Centre, University of Kent, Canterbury CT2 7LZ, UK.
Email:
g.h.murphy{at}kent.ac.uk
Declaration of interest
None. Funding detailed in Acknowledgements.

ABSTRACT
Some people with phenylketonuria who were born before screening
began were
never treated and are still alive. Here we report
that far fewer people with
untreated phenylketonuria were detected
than are thought to exist (about
2000). The majority of those
traced had high support needs, challenging
behaviour and other
symptoms of phenylketonuria. No significant differences
were
found between those who had or had not tried the phenylalanine-restricted
diet. A randomised controlled trial is required to examine
the effect of
trying the low-phenylalanine diet for people
with untreated
phenylketonuria.

INTRODUCTION
Phenylketonuria is a recessively inherited metabolic disorder
which, unless
it is treated early enough with a phenylalanine-restricted
diet, leads to
severe intellectual
disabilities.
1 The
overall
prevalence of phenylketonuria in the UK is about 1 per 10
000
2 and published
guidelines suggest that treatment needs to be
early and
lifelong.
3
Neonatal newborn screening for phenylketonuria began in the late 1960s and
those treated early had a very good
outcome.1 However,
those born before neonatal screening began were not normally treated, as they
already had severe intellectual disabilities, assumed to be irreversible. Our
study aimed to trace all those with untreated phenylketonuria and severe
intellectual disabilities in the UK and to examine their range of
difficulties, as a prelude to a randomised controlled trial of
phenylalanine-restricted diet in people with previously untreated
phenylketonuria.

Methods
A letter and response form were sent to all UK professionals
in a number of
fields (psychiatrists, psychologists and managers
of learning disability
services; dietitians in mental health/learning
disabilities services and
metabolic services; metabolic paediatricians)
asking whether they knew of
anyone with untreated phenylketonuria
and intellectual disabilities. The
survey was also publicised
through the National Society for Phenylketonuria
website and
at conferences. The study was approved by a multisite National
Health Service ethics committee.
Professionals were asked for an anonymised list of people known to them
with untreated phenylketonuria, plus a contact name of someone who could give
further details. These primary contacts were then asked to
complete a brief anonymised questionnaire (described below) regarding the
person with untreated phenylketonuria. To ensure the maximum response rate two
reminder letters were sent to primary contacts if there was no reply. In 11%
of cases, two contacts completed the questionnaire regarding the same person
to provide a measure of interrater reliability (72%).
The questionnaire included questions on: age and gender of the person with
untreated phenylketonuria; their relationship to the respondent; and whether
the person with phenylketonuria had ever tried a low-phenylalanine diet
– if so, for how long. Details of levels of skills, support required,
challenging behaviour, and other symptoms were sought. (Copies of the
questionnaire can be obtained from G.H.M.)
Most data were nominal or ordinal. Analysis was by non-parametric
statistics, including
chi-square.4

Results
Of over 500 letters sent out, 194 replies were received. Of
these, 77 were
positive replies from professionals who knew
of one or more adults with
untreated phenylketonuria; 117 said
they knew of no one with untreated
phenylketonuria. Questionnaires
were then sent to the primary contacts named
in the positive
replies and 98 completed questionnaires were returned (84%
response
rate), regarding adults who had all been untreated in early
life.
Of these 98 people with phenylketonuria, none of whom had been treated in
infancy, 50 had never tried the phenylalanine-restricted diet at all. The
remaining 48 had tried the diet at some point in their lives: 29 had ceased
the diet but 19 were still on it.
Of the 79 untreated people (i.e. 50 never on diet + 29 tried it but not on
diet now), 44% were men. The overall mean age was 47.7 years (s.d.=9.6, range
19–72). The two youngest people were sisters, aged 19 and 22 years, who
had come to the UK from a country that did not have neonatal screening for
phenylketonuria; the next youngest person was 34 years old. Of the 29 people
who had tried the phenylalanine-restricted diet at some point in their lives,
about 50% had tried it for less than 2 years.
The characteristics of the 79 untreated people and their challenging
behaviour are shown in Table 1
(cross-tabulated against whether or not they had ever tried the
phenylalanine-restricted diet). There were no significant differences between
those who had and who had not tried the diet in terms of their
characteristics, challenging behaviour or symptoms.
View this table:
[in this window]
[in a new window]
|
Table 1 Characteristics, challenging behaviour and symptoms of people with
untreated phenylketonuria, not on low-phenylalanine diet
|
The data were also examined for the 19 people, untreated in infancy, who
later tried the phenylalanine-restricted diet and were still on the diet. This
group did not differ significantly from the 79 people who were not on the diet
in terms of their age, gender, levels of skills, challenging behaviours or
symptoms.

Discussion
It has been calculated from the general birth rate (prior to
neonatal
screening for phenylketonuria), together with the
known incidence rate for
phenylketonuria, that there are about
2000 people with untreated
phenylketonuria still alive in the
UK, assuming a life expectancy of 65
years.
5
Jancar
6 argued
that
actual life expectancy for this group is rather lower
at 57 years, but even if
this were the case, we would expect
about 1500 people with untreated
phenylketonuria. In fact,
fewer than 150 people were found. Although it is
possible that
some people with mild phenylketonuria are living relatively
normal lives and are not in contact with services, it is likely
that many
people with untreated phenylketonuria and severe
intellectual disabilities
live in the community, known to learning
disability services, but are not
recognised as having untreated
phenylketonuria. An alternative possibility is
that our survey
strategy missed very large numbers of people with untreated
phenylketonuria (for example, through non-response of professionals),
but it
is difficult to see what survey method might have been
better.
This survey of a relatively large number of people with untreated
phenylketonuria clearly documents the extent of their disabilities and the
significant support needs they have. Their identification is important as
specific intervention with a phenylalanine-restricted diet may potentially
reduce these burdens, even at this late stage, as a number of single-case and
small-scale studies have
suggested.7–10
In our study, there were no significant differences in the levels of
disabilities, challenging behaviours and symptoms between those who had tried
the diet at some point in their lives (whether or not they were still on diet)
and those who had never tried it. However, neither ours nor previous studies
were prospective randomised controlled trials with standardised measures.
There are two main implications of this study. First, general
practitioners, psychiatrists, neurologists, psychologists, community nurses
and dietitians, who may see people with severe intellectual disabilities of
unknown cause, should suspect and screen for phenylketonuria, especially if
the person is more than 35 years old (or was born in a country without
neonatal screening), needs 24-h support, and has challenging behaviours and
symptoms of phenylketonuria (eczema, epilepsy, mousey body
odour, and a fair complexion). The second implication is that there is a need
for a properly designed randomised control trial to examine whether a
phenylalanine-restricted diet really is of help to this very disabled group of
people.

ACKNOWLEDGMENTS
We are grateful to all at SHS International, especially Pat
Portnoi, for
their help with this survey, and to the Wellcome
Trust for funding.

REFERENCES
1 - Koch R, de la Cruz F. Historical aspects and overview of research
on phenylketonuria. Ment Retard Dev Disabil Res Rev 1999; 5: 101
–3.[CrossRef]
2 - Woolff OH, Smith I, Carson N, Graham PJ, Kromrower GM, Turnbull AC,
Clayton BE, Mahler R, Sutherland I. Routine neonatal screening for
phenylketonuria in the United Kingdom 1964–1978. BMJ (Clin
Res Ed) 1981; 282: 1680
–4.[Abstract/Free Full Text]
3 - Waisbren S, Schnell RR, Levy HL. Diet termination in children with
phenylketonuria: a review of psychological assessments used to determine
outcome. J Inherit Metab Dis 1980;
3: 149
–53.[CrossRef][Medline]
4 - Howell DC. Statistical Methods for
Psychology (4th edn). Duxbury Press, 1997
.
5 - Brown MCJ, Guest JF. Economic impact of feeding a phenylalanine
restricted diet to adults with previously untreated phenylketonuria.
J Intellect Disabil Res 1999;
43: 30
–7.[CrossRef][Medline]
6 - Jancar J. Increased life expectancy in people with untreated
phenylketonuria. J Intellect Disabil Res 1998; 42: 97
–9.[CrossRef][Medline]
7 - Hoskin RG, Sasitharan T, Howard R. The use of a low phenylalanine
diet with amino acid supplement in the treatment of behaviour problems in a
severely mentally retarded adult female with phenylketonuria. J
Intellect Disabil Res 1992;
36: 183
–91.[Medline]
8 - Yannicelli S, Ryan A. Improvements in behaviour and physical
manifestations in previously untreated adults with phenylketonuria using a
phenylalanine restricted diet: a national survey. J Inherit Metab
Dis 1995; 18: 131
–4.[CrossRef][Medline]
9 - Fitzgerald B, Morgan J, Keene N, Rollinson R, Hodgson A,
Dalrymple-Smith J. An investigation into diet treatment for adults with
previously untreated phenylketonuria and severe intellectual disability.
J Intellect Disabil Res 2000;
44: 53
–9.[Medline]
10 - Koch R, Moseley K, Ning J, Romstad A, Guldberg P, Guttler F.
Long-term beneficial effects of the pheylalanine-restricted diet in
late-diagnsoed individuals with phenylketonuria. Mol Genet
Metab 1999; 67: 148
–55.[CrossRef][Medline]
Received for publication September 11, 2007.
Revision received December 19, 2007.
Accepted for publication January 18, 2008.
Related articles in BJP:
- From the Editors desk
- Peter Tyrer
BJP 2008 193: 524.
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
P J Lee, A Amos, L Robertson, B Fitzgerald, R Hoskin, M Lilburn, E Weetch, and G Murphy
Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet
J. Neurol. Neurosurg. Psychiatry,
June 1, 2009;
80(6):
631 - 635.
[Abstract]
[Full Text]
[PDF]
|
 |
|